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Endothelial injury anddysfunction (ED) represent a link
between cardiovascular risk factors promoting hyper-
tension and atherosclerosis, the leading cause of
death in Western populations. High-density lipopro-
tein (HDL) is considered antiatherogenic and known
to prevent ED. Using HDL from children and adults
with chronic kidney dysfunction (HDLCKD), a popula-
tion with high cardiovascular risk, we have demon-
strated thatHDLCKD incontrast toHDLHealthypromoted
endothelial superoxide production, substantially
reduced nitric oxide (NO) bioavailability, and subse-
quently increased arterial blood pressure (ABP). We
have identified symmetric dimethylarginine (SDMA)
in HDLCKD that causes transformation fromphysiolog-
ical HDL into an abnormal lipoprotein inducing ED.
Furthermore, we report that HDLCKD reduced endo-
thelial NO availability via toll-like receptor-2 (TLR-2),
leading to impaired endothelial repair, increased
proinflammatory activation, and ABP. These data
demonstrate how SDMA can modify the HDL particle
to mimic a damage-associated molecular pattern
that activates TLR-2 via a TLR-1- or TLR-6-corecep-
tor-independent pathway, linking abnormal HDL to
innate immunity, ED, and hypertension.
INTRODUCTION
Atherosclerotic cardiovascular disease and hypertension are
highly prevalent in Western populations and are the leading754 Immunity 38, 754–768, April 18, 2013 ª2013 Elsevier Inc.cause of death (Lloyd-Jones et al., 2010). Endothelial injury
and dysfunction (ED) represent a common link of all cardio-
vascular risk factors acting upon the vascular system to pro-
mote development and progression of atherosclerosis and
hypertension (Berenson et al., 1998; Landmesser et al., 2004;
Libby et al., 2011; Ross, 1999). An important characteristic
of ED is the dysbalance between reduced atheroprotective
endothelial nitric oxide (NO) availability and an increased
production of reactive oxygen species (ROS) (Landmesser
et al., 2004), promoting vasoconstriction, inflammatory activa-
tion, and impaired endothelial repair (Kubes et al., 1991; Pober
and Sessa, 2007).
Interestingly, lipids and lipoproteins critical in atherogenesis
are also involved in immunological processes of the innate and
adaptive immune response (Hansson and Hermansson, 2011).
Arterial endothelial cells express signaling pattern-recognition
receptors of the innate immune system, such as toll-like
receptor-2 (TLR-2) and TLR-4 (Hansson and Hermansson,
2011). Innate immunity is mainly based on recognition of patho-
gens by pattern recognition receptors. Among these receptors,
TLRs have been studied extensively. TLRs recognize a broad
variety of exogenous pathogen-associated molecular pattern
(PAMP) and endogenous danger-associated molecular pattern
(DAMP) (Kawai and Akira, 2011). TLRs have been suggested to
play a crucial role in the pathogenesis of atherosclerotic diseases
(Mullick et al., 2005) (Edfeldt et al., 2002; Favreet al., 2007;Mullick
et al., 2008). Recent evidence suggests that known atherogenic
lipids, i.e., oxidized phospholipids and oxidized low-density lipo-
protein (LDL), can trigger a TLR-2 dependent response and
apoptosis in macrophages (Seimon et al., 2010). However, the
modeof activationof endothelial TLRs inatherosclerosis and their
relation to endothelial dysfunction remains to be characterized.
Based on a rather rigid picture of atherosclerosis, for a long
time LDL was thought to promote the development of ED and
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opment of ED and atherosclerosis. However, recent evidence
suggests that endothelial effects of HDL can be highly heteroge-
neous under several disease conditions (Charakida et al., 2009;
Sorrentino et al., 2010). Furthermore, in contrast to observational
trials revealing a protective effect of high HDL plasma concentra-
tions, a recent study documented that genetic mechanisms
raising HDL cholesterol plasma concentrations are not associ-
ated with a lower risk for myocardial infarction (Voight et al.,
2012).
Focusing on HDL, we sought to determine whether modifica-
tion of HDL may alter its endothelial effects by modulation of the
innate immune system. Therefore, we isolated HDL frompatients
with chronic kidney dysfunction (CKD) as a population with
a particularly high risk for cardiovascular events and mortality
and a high prevalence of ED and hypertension (Go et al., 2004;
Klag et al., 1996). In marked contrast to previous reports, we
observed that HDLCKD not only lost its endothelial-protective
properties, but rather became a noxious particle that induced
endothelial dysfunction and increased arterial blood pressure.
We observed that symmetric-dimethylarginine (SDMA) in the
HDL fraction was responsible for adverse vascular actions of
this ‘‘toxic’’ HDL. Moreover, we could demonstrate that such
a modified HDL induced an endothelial TLR-2 response via a
TLR-1- and TLR-6-coreceptor and NF-kB-independent pathway
resulting in an enhanced ROS and suppressed endothelial NO
bioavailability.
RESULTS
Participants
To examine the endothelial effects of HDL in a cardiovascular
‘‘high-risk’’ population, we isolated HDL from adults (n = 45)
and children (n = 22) with different degrees of chronic kidney
dysfunction and age- and gender-matched healthy control
subjects (n = 15 adults and n = 10 children; see Tables S1 and
S2 available online).
HDL from Patients with Chronic Kidney Disease Induces
Endothelial Dysfunction and Increases Arterial Blood
Pressure
We analyzed NO production in human aortic endothelial cells
(HAEC) incubated with HDL isolated from adult patients with
chronic kidney dysfunction (HDLCKD) and from corresponding
healthy subjects (HDLHealthy) by electron spin resonance (ESR)
spectroscopy. HDLHealthy stimulated endothelial NO production,
but in marked contrast, HDLCKD strongly inhibited NO produc-
tion in HAECs (Figure 1A). Notably, HDL from patients with mildly
reduced kidney function already substantially inhibited endothe-
lial cell NO release (Figure 1A). Both effects were observed to be
dose-dependent (Figure 1B).
In a next step, we examined whether chronic kidney disease
per se and not concomitant diseases are responsible for these
adverse effects of HDL on endothelial NO production. For this
purpose, we isolated HDL from children with an impaired kidney
function and measured its effects on the endothelial NO produc-
tion. Importantly, HDLCKD from children substantially inhibited
endothelial NO production, whereas HDLHealthy from children
induced endothelial NO production (Figure 1C).A reduced endothelial NO production has been shown to
increase ABP (Huang et al., 1995). To address the effects of
HDL on ABP, we injected HDLHealthy and HDLCKD into C57BL/
6J mice and measured ABP before and 90 min after HDL injec-
tion. HDLHealthy decreased systolic ABP (12 ± 2 mmHg),
whereas HDLCKD significantly increased ABP in vivo (+9 ±
2 mmHg, Figure 1D). These effects were completely abolished
in Nos3/ mice (Figure 1E) pointing to endothelial NO synthase
(eNOS) mediating the different effects of HDL on ABP.
It is well established that superoxide radicals can directly react
with NO, reducing its bioavailability and inducing hypertension
(Landmesser et al., 2002). We therefore analyzed the effect of
HDL on endothelial cell superoxide production in HAECs and
observed that HDLCKD strongly induced endothelial superoxide
production. In contrast, treatment with HDLHealthy did not change
basal endothelial superoxide release (Figures 1F and 1G).
SDMA but Not ADMA Is Associated to HDL and Inhibits
Endothelial NO Production
We hypothesized that ADMA, an endogenous inhibitor of eNOS
that accumulates in the plasma in different clinical disease
conditions (e.g., chronic kidney disease [Fliser et al., 2005]),
may be involved in this process. We fractionated plasma from
healthy subjects and patients with reduced kidney function and
measured ADMA in the HDL fraction using a mass spectrometry
approach (ESI-MS/MS). However, although ADMA serum
concentrations were elevated in patients with chronic kidney
diseases (Figures S1A and S2–S4), we could not detect signifi-
cant amounts of ADMA in the HDL fraction. Instead, we found
its structural isomer SDMA in the HDL fraction in a substantial
amount, but only in samples obtained frompatients with reduced
kidney function (Figure 2A).
To address whether SDMA converts physiological HDL into
‘‘noxious’’ HDL, we supplemented HDL and LDL from healthy
donors with SDMA or ADMA and measured subsequently the
effects on endothelial NO production. Interestingly, only HDL
supplemented with SDMA inhibited endothelial NO production,
whereas neither supplementation of HDLwith ADMA nor supple-
mentation of LDL with ADMA and SDMA caused any significant
changes of the effects of the lipoproteins on endothelial NO
release. The amount of SDMA in the HDL fraction after supple-
mentation was comparable to that observed in HDLCKD. Notably,
SDMA alone, in the absence of HDL, did not significantly change
endothelial NO production (Figure 2B). Supplementation of HDL
(HDLSDMA) with increasing concentrations of SDMA dose-
dependently suppressed endothelial cell NO production (Fig-
ure 2C). Similar to the effect of HDL from patients with reduced
kidney function, HDLSDMA induced basal endothelial superoxide
production (Figure 2D).
Furthermore, we supplemented reconstituted HDL (rHDL)
consisting of Apo-A1:POPC:cholesterol in a molar ratio of
1:100:10 with and without SDMA and measured its effect on
endothelial cell NO production. Supplementation of rHDL with
SDMA reduced endothelial NO production (Figure 2E). More-
over, after supplementation with SDMA, apolipoprotein A1
(Apo-A1) inhibited endothelial NO production, whereas Apo-A1
without SDMAdid not significantly affect endothelial NO produc-
tion (Figure 2E). This indicates that SDMA may associate with
Apo-A1, the major apolipoprotein of HDL.Immunity 38, 754–768, April 18, 2013 ª2013 Elsevier Inc. 755
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Figure 1. HDL from Patients with Kidney Dysfunction Induces Endothelial Dysfunction and Hypertension
(A) NO production in HAEC determined by ESR spectroscopy after incubation with HDL (50 mg/ml, 1 hr) from adult patients with different degrees of kidney
dysfunction and healthy control subjects (n = 15 per group).
(B) NO production in HAEC determined by ESR spectroscopy after incubation with different concentrations of HDL as indicated (1 hr).
(C) NO production in HAEC determined by ESR spectroscopy after incubationwith HDL (50 mg/ml, 1 hr) from children with kidney dysfunction and healthy children
as control.
(D) D Systolic ABP in WT mice 90 min after intravenous (i.v.) injection of HDL (15 mg/kg, n = 5–6 per group).
(E) D Systolic ABP in Nos3/ (eNOS) mice 90 min after i.v. injection of HDL (50 mg/kg).
(F) Superoxide production in HAEC determined by ESR spectroscopy after incubation with HDL (50 mg/ml, 1 hr).
(G) ESR spectra of endothelial superoxide production after stimulation with HDL.
All data are presented as mean ± SEM and are representative for at least three independent experiments. See also Tables S1 and S2.
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Figure 2. HDL Supplemented with SDMA Induces Endothelial Dysfunction and Hypertension
(A) Amounts of ADMA and SDMA associated to HDL from healthy subjects and patients with kidney dysfunction determined by ESI-MS/MS.
(legend continued on next page)
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HDL Promotes Endothelial Dysfunction via TLR-2HDL fromhealthy subjects is known tostimulateendothelialNO
production by Akt kinase-dependent eNOS phosphorylation via
activation of endothelial scavenger receptor B-I (SR-BI) or sphin-
gosine-1 phosphate receptors (Acton et al., 1996; Nofer et al.,
2004). Here, we found—in contrast to HDLHealthy—that HDLCKD
and HDLSDMA reduced phosphorylation of Akt (Ser473), leading
to a reduced eNOS-activating phosphorylation (Ser1177) and a
enhanced eNOS-inhibiting phosphorylation (Thr495) (Figure 2F;
Figures S1E–S1G). Therefore, we hypothesized that such modi-
fied HDL changes its affinity to these endothelial receptors
mediating the protective endothelial effects of HDLHealthy.
Interestingly, binding of HDLHealthy andHDLSDMA to endothelial
cells did not differ significantly (Figure 2G). However, the interac-
tion of HDLSDMA at 37C (i.e., cell association) was significantly
lower compared to HDLHealthy, indicating that SDMA changes
the association of HDL with endothelial cells (Figure S1B). To
further examine the binding affinity of HDLSDMA to the HDL
receptor SR-BI, we performed additional binding studies using
HEK293 cells transfected with hSRB-I or with an empty vector
(control). Here, binding of HDLHealthy and HDLSDMA to HEK cells
transfected with hSR-BI did not differ significantly (Figure S1C).
We repeated the experiment using rHDL supplemented with and
without SDMA. Also here, we did not observe a difference in the
binding capacity of HDLHealthy and HDLSDMA to SR-BI (Fig-
ure S1D). Collectively, supplementation of 125I-labeled HDL
with SDMA reduced the association, but not the specific binding
to SR-BI or endothelial cells.
HDL Supplemented with SDMA Activates Endothelial
Toll-like Receptor 2
TLR-2 and TLR-4 represent receptors of the innate immune
system involved in recognition of pathogen-associated lipopro-
teins (Takeuchi and Akira, 2010). Both TLR-2 and TLR-4 are
highly expressed on HAECs (Figures S5A and S5B). We
measured endothelial NO production in HAECs stimulated with
HDLHealthy, HDLCKD, or HDLSDMA in the presence or absence of
specific neutralizing antibodies against TLR-2 and TLR-4. We
observed that blocking of TLR-2 but not TLR-4 restored the
effects of HDLCKD and HDLSDMA on endothelial NO production
(Figure 3A). Importantly, the neutralizing antibodies did not affect
NO production in the presence of HDLHealthy. Consistently, injec-
tion of HDLCKD into Tlr2/mice, but not in Tlr4/mice, failed to
increase ABP (Figure 3B).
To examine whether TLR-2 on circulating mononuclear cells
contributes to the effect of HDLCKD on ABP, we analyzed wild-
type (WT) and Tlr2/ bone-marrow chimeric mice, which were
sublethally irradiated and transplanted with bone marrow from(B) Effect of SDMA alone (4 mM), healthy HDL (50 mg/ml) or LDL (100 mg/ml) su
lipoprotein) on endothelial NO production.
(C) Effect of HDLHealthy supplemented with different concentrations of SDMA (0.5
(D) Effect of HDL (50 mg/ml, 1 hr) supplemented with SDMA (0.5 mmol/g HDL pro
(E) Effect of rHDL (50 mg/ml) or Apo-A1 (25 mg/ml) supplemented with SDMA (0.5
(F) Phosphorylation of Akt at Ser473, eNOS activating phosphorylation at Ser117
analysis in HAEC incubated with HDL (50 mg/ml) for 10 min as indicated.
(G) Quantification of Akt phosphorylation at Ser473 in HAEC incubated with HDL
(H) Quantification of eNOS phosphorylation at Ser1177 in HAEC incubated with
(I) Quantification of eNOS phosphorylation at Thr495 in HAEC incubated with HD
(J) Effect of SDMA-supplementation on endothelial binding of 125I-HDL.
All data are presented as mean ± SEM and are representative for at least three i
758 Immunity 38, 754–768, April 18, 2013 ª2013 Elsevier Inc.WT or Tlr2/ mice (Figure 3C). We observed an increased
ABP in HDLCKD-treated mice with intact TLR-2 expression on
vascular cells but lack on bone-marrow-derived circulating
mononuclear cells. These data suggest that TLR-2 on the endo-
thelium but not on circulating mononuclear cells mediates the
adverse effects of HDLCKD on ABP. Of note, the response of
ABP did not differ between WT and Tlr2/ mice after injection
of the eNOS inhibitor L-NAME (Figure 3D).
To assess the interaction between HDLSDMA and TLR-2, we
transfected endothelial cells with a plasmid encoding for human
TLR-2 without its intracellular Toll/Interleukin-1 receptor (TIR)-
domain (TLR2-DTIR-HA) and incubated them with fluorescent-
labeled HDL. As a control, we used a plasmid encoding human
TLR-5 (TLR2-DTIR-HA), which is also expressed on the cell
surface (Ramos et al., 2004) (Figures S5C and S5D). Overexpres-
sion of TLR-2 increased the interaction of endothelial cells with
HDLSDMA, whereas overexpression of TLR-5 did not change the
interactionwithHDLand endothelial cells (Figure 3E; Figure S5E).
Modified HDL Does Not Activate NF-kB-Dependent
TLR-2 Signaling
Next, we asked whether activation of TLR-2 in the absence of
HDLCKD or HDLSDMA is sufficient to inhibit endothelial NO
production. Pam3CSK4 and FSL-1 are synthetic lipopeptides,
known to bind to TLR-2 (Fujita et al., 2003; Jin et al., 2007). Treat-
ment of HAECs with Pam3CSK4 or FSL-1 inhibited endothelial
NO production. This effect was completely abolished in the pres-
ence of anti-TLR-2 neutralizing antibodies (Figure 4A). In
contrast, the TLR-4 agonist LPS increased endothelial NO
production in a TLR-4 dependent manner (Figure 4A). In vivo,
a single-dose of Pam3CSK4 was sufficient to significantly
increase ABP in WT, but not in Tlr2/ mice (Figure 4B).
Recognition of bacterial lipoproteins usually requires forma-
tion of heterodimer complexes of TLR-2 with TLR-1 or TLR-6,
respectively (Alexopoulou et al., 2002; Fujita et al., 2003; Sandor
et al., 2003). Pam3CSK4 is recognized by the TLR-1-TLR-2 and
FSL-1 by the TLR-2-TLR-6 heterodimer resulting in NF-kB
pathway activation and proinflammatory cytokine release (Beu-
tler, 2004). We used human embryonic kidney (HEK)-Blue
TLR-2 reporter cells to address whether modified HDL activates
the NF-kB pathway. Surprisingly, in contrast to Pam3CSK4 and
FSL-1, both HDLCKD and HDLSDMA failed to activate NF-kB
pathway in the reporter cells under basal conditions (Figure 4C).
Pam3CSK4 induced release of cytokines in bone-marrow-
derivedmacrophages fromWT, but not from Tlr2/mice, and in
human peripheral blood mononuclear cells (PBMC; Table S3).
In contrast, production of these cytokines was not stimulatedpplemented with or without SDMA or ADMA (4 mM equivalent to 0.5 mmol/g
mmol/g HDL protein) on endothelial NO production.
tein) on endothelial superoxide production.
mmol/g protein) on endothelial NO production.
7 and eNOS inhibiting phosphorylation at Thr495 determined by immunoblot
(50 mg/ml) for 10 min.
HDL (50 mg/ml) for 10 min.
L (50 mg/ml) for 10 min.
ndependent experiments. See also Figure S1.
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Figure 3. Modified HDL Activates TLR-2 to Induce Endothelial Dysfunction and Hypertension
(A) Effect of TLR-2 and TLR-4 inhibition using a blocking antibody (10 mg/ml, each) or an isotype control antibody (10 mg/ml) on endothelial NO production after
incubation with HDLHealthy, HDLCKD, and HDLSDMA (0.5 mmol/g SDMA, 50 mg/ml HDL).
(B) D ABP in Tlr2/ and Tlr4/ mice 90 min after i.v. injection of HDLHealthy and HDLCKD (15 mg/kg HDL).
(C)D ABP 90min after i.v. injection of HDLHealthy and HDLCKD (15mg/kg HDL) inWT, Tlr2/mice 6weeks after bone-marrow transplantation fromWT and Tlr2/
mice as indicated.
(legend continued on next page)
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Immunity
HDL Promotes Endothelial Dysfunction via TLR-2by HDLCKD and HDLSDMA. Notably, neither Pam3CSK4 nor HDL
did affect cytokine release in HAEC as determined by ELISA
(Table S3) or intracellular cytokine staining (Figures S6C and
S6E). Furthermore, we used neutralizing antibodies against
TLR-1, TLR-2, and TLR-6 to block NF-kB activation in the
HEK-Blue TLR-2 reporter cells stimulated with Pam3CSK4 and
FSL-1. As expected, blocking of either TLR-1 or TLR-6 and
TLR-2 almost completely abolished Pam3CSK4 or FSL-1
induced NF-kB activation (Figure 4D).
TLR-1- or TLR-6-Coreceptor Activation Is Not Required
to Induce TLR-2 Mediated Endothelial Dysfunction
We determined the presence of TLR-1- and TLR-6-coreceptors
on HAEC by flow cytometry. Of note, in contrast to human
PBMC, HAEC only expressed TLR-2 on their surface, whereas
TLR-1 and TLR-6 were not detectable (Figures S6A and S6B).
Next, we addressed whether TLR-1 or TLR-6 blockade can
restore NO production in HAEC treated with Pam3CSK4 or
HDLCKD. In contrast to TLR-2 blockade, addition of anti-TLR-1
and/or TLR-6 neutralizing antibodies had no effect on endothelial
NO production in the presence of Pam3CSK4, HDLCKD, or
HDLHealthy (Figure 5A). Collectively, our data suggest that modi-
fiedHDL activates TLR-2 inducing a TLR-1- and TLR-6-corecep-
tor-independent pathway in endothelial cells. Consistently,
absence of TLR-1 (Tlr1/mice) and TLR-6 (Tlr6/mice) in vivo
did not prevent the effect of HDLCKD on ABP (Figure 5B).
Furthermore, we analyzed endothelial superoxide production
in response to Pam3CSK4 and FSL-1 in the presence or absence
of neutralizing antibodies against TLR-2, TLR-1, or TLR-6. We
observed elevated superoxide production in HAEC treated with
Pam3CSK4 and FSL-1. Blockade of TLR-2, but not TLR-1 and/
or TLR-6, prevented this effect (Figure 5C).
Activation of Endothelial TLR-2 Inhibits eNOS Activating
Pathways and Stimulates NADPH Oxidase
Next, we assessed the molecular mechanisms on how TLR-2
activation affects endothelial superoxide and nitric oxide pro-
duction. At first, we analyzed the effect of the TLR-2 agonist
Pam3CSK4 on endothelial Akt and eNOS phosphorylation.
Comparable to HDLCKD and HDLSDMA, Pam3CSK4 reduced Akt
phosphorylation at Ser473 and thereby induced eNOS-inhibiting
phosphorylation at Thr495 (Figure 6A). In addition, it has been
shown that TLR-2 activation inducesNADPH oxidase to produce
ROS in monocytes and macrophages (Beaulieu et al., 2011);
however, its role in endothelial cells remained unclear. By
measuringendothelial superoxideproduction after preincubation
with a specific chemical inhibitor of NADPH oxidase (VAS-2870),
we demonstrated a pivotal role for NADPH oxidase in TLR-2
induced endothelial superoxide production. By using L-NAME,
an eNOS inhibitor, we ruled out eNOS uncoupling as an imme-
diate source of TLR-2-mediated superoxide production (Fig-
ure 6B). Notably, inhibition of NADPH oxidase almost completely
prevented the effect of HDLCKD, HDLSDMA, and Pam3CSK4 on
endothelial nitric oxide production (Figure 6C). TLR-2 activation(D) D ABP in WT and Tlr2/ mice 30 min after i.v. injection of L-NAME (17 mg/k
(E) Interaction of Atto-488-labeled HDL (20 mg/ml, 30 min) with endothelial cells tra
fluorescence was recorded using flow cytometry.
All data are presented as mean ± SEM and are representative for at least three i
760 Immunity 38, 754–768, April 18, 2013 ª2013 Elsevier Inc.is known to induce phosphorylation of c-Jun N-terminal kinase
(JNK), and we have recently shown that activation of JNK in
endothelial cells induces endothelial superoxide production by
increasing NADPH oxidase activity (Cabanski et al., 2008; Osto
et al., 2008; Shi et al., 2011). Here, we observed that Pam3CSK4
induces JNK phosphorylation in HAEC (Figure 6D; Figure S7A).
Accordingly, SP600125, a JNK inhibitor, abolished the effect of
HDLCKD, HDLSDMA, and Pam3CSK4 on endothelial superoxide
and nitric oxide production (Figures 6E and 6F).
HDLCKD and HDLSDMA Impair Endothelial Repair
and Promote Inflammatory Activation
We and others have previously demonstrated that reduced NO
bioavailability along with enhanced superoxide production may
also impair other endothelial functions, such as endothelial repair
after injury and its anti-inflammatory capacity (Kubes et al., 1991;
Sorrentino et al., 2007). To elucidate whether modified HDL also
affects these endothelial properties by inhibiting endothelial NO
production, we finally assessed the effect of modified HDL on
endothelial repair and inflammation.
In an endothelial wound healing assay, HDLHealthy strongly
stimulated endothelial cell migration, whereas HDLCKD inhibited
endothelial migration (Figures S8A and S8B). In line with these
in vitro observations, HDLCKD and HDLSDMA inhibited endothelial
repair in vivo in a carotid artery injury model (Figures 7A and 7B).
This was in marked contrast to HDLHealthy, which promoted
endothelial repair. In Tlr2/mice, we observed that HDLCKD re-
gained its capacity to promote endothelial repair (Figure 7C).
These findings underscore the important role of TLR-2 to
mediate adverse endothelial effects of HDLCKD and HDLSDMA.
Furthermore, we observed that HDLCKD increased endothelial
proinflammatory activation as determined by a higher amount of
adhering mononuclear cells to a TNF-a-stimulated endothelial
monolayer, which was in contrast to HDLHealthy (Figures 7D and
7E). Accordingly,HDLCKDandHDLSDMA increasedendothelial ex-
pressionof vascular cell adhesionmolecule-1 (VCAM-1),whereas
HDLHealthy significantly reduced VCAM-1 expression on endothe-
lial cells (Figure 7F). Next, we analyzed the effect of NO on TNF-a
induced VCAM-1 expression in the presence of HDL. Inhibition
of eNOS through L-NAME reduced the anti-inflammatory effects
of HDLHealthy by enhancing endothelial VCAM-1 expression,
whereas supplementation of NO using a solid NO-donor, di-
ethylenetriamine-nitric oxide (DetaNO), restored the anti-inflam-
matory function of the endothelium by reducing endothelial
VCAM-1 expression (Figure 7F). Taken together, these results
clearly suggest that a reduced endothelial NO bioavailability
inducedbyHDLCKDandHDLSDMA represents amajormechanism
explaining adverse endothelial effects of modified HDL.
DISCUSSION
Our results demonstrate that HDL from children and adult
patients with CKD substantially inhibits endothelial NO pro-
duction and thereby increases ABP. We have identifiedg).
nsfected with a plasmid containing hTLR2-DTIR-HA or hTLR5-DTIR-HA. Mean
ndependent experiments. See also Figure S2.
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Figure 4. Modified HDL Does Not Activate NF-kB-Dependent TLR-2 Signaling
(A) Endothelial NO production after stimulation (1 hr) with the TLR-1-2 agonist Pam3CSK4 (1 mg/ml), TLR2-6 agonist FSL-1 (100 ng/ml) and the TLR-4 agonist LPS
(1 mg/ml) with or without preincubation with blocking antibodies against TLR-2 or TLR-4 (10 mg/ml).
(B) D Systolic ABP in WT and Tlr2/ mice 90 min after i.v. injection of Pam3CSK4 (5 mg/kg).
(C) TLR-2 activity in HEK cells cotransfectedwith TLR-2 and SEAP under control of NF-kBandAP-1 after stimulationwith Pam3CSK4 (1 mg/ml), FSL-1 (100 ng/ml),
HDL (50 mg/ml), or SDMA (4 mmol/L) for 18 hr (***p < 0.001 compared to untreated cells).
(D) TLR-2 activity in HEK cells cotransfected with TLR-2 and SEAP under control of NF-kB and AP-1 after preincubation with blocking antibodies targeting TLR-2,
TLR-4, TLR-1, TLR-6, or isotype control (10 mg/ml) for 1 hr and subsequent stimulation with Pam3CSK4 (1 mg/ml) or FSL-1 (100 ng/ml) for 18 hr (**p < 0.01
compared to Pam3CSK4 treated cells, ### p < 0.001 and ## p < 0.01 compared to FSL-1 treated cells).
All data are presented as mean ± SEM and are representative for at least three independent experiments. See also Figure S3 and Table S3.
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HDL Promotes Endothelial Dysfunction via TLR-2accumulation of SDMA in HDL from subjects with even mild
CKD as the culprit converting HDL into a noxious particle.
Furthermore, we have shown that this abnormal HDL activates
endothelial TLR-2 via a TLR-1- and TLR-6-coreceptor-indepen-
dent alternative pathway impairing endothelial repair and
enhancing endothelial proinflammatory activation.We have described the effects of HDL from patients with CKD
as a population with a particularly high cardiovascular morbidity
and mortality (Go et al., 2004; Van Biesen et al., 2007). In healthy
individuals, endothelial NO production stimulated by HDL
serves as an important stimulus to preserve endothelial function
(Bisoendial et al., 2003; Landmesser et al., 2004; Nofer et al.,Immunity 38, 754–768, April 18, 2013 ª2013 Elsevier Inc. 761
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HDL Promotes Endothelial Dysfunction via TLR-22004; Spieker et al., 2002; Yuhanna et al., 2001). By contrast,
in the present study, we found that HDL from patients with
CKD almost completely suppressed endothelial NO production
in a dose-dependent manner. Importantly, this adverse effect
of HDLCKD was already present with HDL from patients with an
early stage of CKD and children with CKD. Moreover, infusion
of HDLCKD into mice significantly increased ABP. This observa-
tion is of overriding importance, because hypertension is a strong
promoter of cardiovascular disease and frequently observed in
patients with CKD (Peterson et al., 1995). In contrast to previous
reports describing ‘‘dysfunctional HDL,’’ we have demonstrated
here that HDLCKD not only loses its vasoprotective properties but
rather changes into a noxious particle strongly promoting endo-
thelial dysfunction and hypertension.
ADMA, a methylation product of L-arginine residues, is an
endogenous eNOS inhibitor increased in patients with CKD (Bo¨-
ger et al., 1998; Fliser et al., 2005; Kielstein et al., 2002; Zoccali
et al., 2001). By using a modified mass-spectrometry approach,
we ruled out the presence of ADMA in the HDL fraction. Surpris-
ingly, we detected substantial amounts of SDMA, an isomer of
ADMA, in HDLCKD, but not in HDLHealthy. We and others have
previously demonstrated that SDMA serum concentrations are
elevated in several clinical conditionssuchasCKDandpulmonary
arterial hypertension (Kielsteinet al., 2002;Pullamsetti et al., 2005;
Schepers et al., 2011). Although SDMA is thought to be function-
ally inactive, several studies highlighted its predictive value for
cardiovascular events (Bode-Bo¨ger et al., 2006; Meinitzer et al.,
2011). Interestingly, supplementation of HDL with SDMA in con-
centrations as measured in patients with CKD resulted in delete-
rious effects of HDLSDMA on endothelial NO production and
endothelial repair by inhibiting Akt-dependent eNOS phosphory-
lation. Because supplementation of LDL with SDMA did not
change its effect on endothelial NO production, we hypothesized
that SDMA may be associated to the protein part of the HDL
complex. Indeed, we observed that rHDL and Apo-A1 supple-
mented with SDMA reduced endothelial NO production, which
indicates that SDMA may associate to Apo-A1. These findings
indicate that the presenceof SDMA in theHDLparticlemay repre-
sent a mechanism leading to deterioration of HDL’s vascular
effects and its transformation into a proatherogenic particle.
HDLHealthy exerts its endothelial-atheroprotective effects by
binding to the endothelial scavanger receptor SR-BI or S1P3
receptors as well as by activating ATP binding cassette trans-
porter-1 (ABCG-1) (Acton et al., 1996; Assanasen et al., 2005;
Nofer et al., 2004; Terasaka et al., 2008; Yuhanna et al., 2001).
Our data indicate that supplementation with SDMA does not
change the affinity of HDL to the receptor SR-BI. Therefore, we
focused on receptors, which are associated with abnormal
endothelial activation. TLR-2 and TLR-4 are both expressed on
endothelial cells (Edfeldt et al., 2002; Grote et al., 2010) and
known to be activated by microbial lipoprotein patterns (Takeu-Figure 5. Activation of TLR-2 Stimulates Endothelial Production of RO
(A) Endothelial NO production after preincubation with TLR-1 and/or TLR-6 neutr
stimulation with Pam3CSK4 (1 mg/ml) or HDL (50 mg/ml, 1 hr).
(B) D Systolic ABP in Tlr1/ and Tlr6/ mice 90 min after i.v. injection of HDLHe
(C) Endothelial superoxide production after preincubation with a TLR-1, TLR-2, or T
with Pam3CSK4 or FSL-1 (1 mg/ml or 100 ng/ml, 1 hr; *p < 0.05 compared to Pa
All data are presented as mean ± SEM and are representative for at least three ichi and Akira, 2010). Indeed, activation of TLR1-TLR-2, TLR-2-
TLR-6, or TLR-4 by microbial lipoproteins initiates defense
mechanisms of the innate immunity against infectious pathogens
(Brightbill et al., 1999; Roux et al., 2011). Interestingly, it has been
shown that TLR-2 may also play an important role in develop-
ment of atherosclerosis (Mullick et al., 2005, 2008). Moreover,
TLR-2 deficiency has been demonstrated to ameliorate ED after
coronary endothelial injury (Favre et al., 2007). However, the
underlying molecular mechanisms remained widely unknown.
Notably, in the present study, the selective inhibition or genetic
deficiency of TLR-2, but not TLR-4, almost completely abro-
gated the adverse effects of modified HDL on endothelial NO
bioavailability, endothelial repair, and ABP. Recent evidence
suggests that circulating cells of the lymphoid and myeloid
compartment are crucially involved in the pathogenesis of hyper-
tension (Harrison et al., 2011). Blood pressure measurements
using WT and Tlr2/ bone marrow chimeras suggested that
TLR-2 expression on endothelial cells, rather than circulating
mononuclear cells, mediated the adverse effect of HDLCKD on
ABP. This indicates that the presence of SDMA transforms
HDL toward a phenotype that activates this innate immune
receptor on the endothelium.
It is well known that activation of TLR-1-TLR-2 and TLR-2-
TLR-6 by their classical bacterial ligands induces the NF-kB-
dependent production of cytokines and other proinflammatory
molecules in a variety of cell types (Alexopoulou et al., 2002;
Beutler, 2004; Fujita et al., 2003; Sandor et al., 2003). Surpris-
ingly, we observed that abnormal HDL did not induce TLR-1-
TLR-2 or TLR-2-TLR-6-mediated NF-kB activation and subse-
quent cytokine release in endothelial cells or PBMC. Notably,
blockade of TLR-1 and/or TLR-6 did not affect endothelial NO
production and superoxide production in response to classical
TLR-2 ligands or HDLCKD and HDLSDMA. Thus, we were able to
document that the effect of TLR-2 activation on endothelial NO
production is NF-kB independent.
It has recently been shown that TLR-2 activation can induce
ROS production in monocytes and macrophages (Beaulieu
et al., 2011; West et al., 2010, 2011). In the present study, we
could demonstrate that endothelial activation of TLR-2 induced
endothelial ROS production. Of note, TLR-2-induced ROS
production was abolished after TLR-2 and not TLR-1 or TLR-6
blockade. This indicates that TLR-2 stimulates endothelial
ROS production thereby inhibiting NO bioavailability via a
TLR-1- and TLR-6-coreceptor-independent alternative path-
way. Furthermore, we demonstrated that the TLR-2 induced
NF-kB-dependent cytokine release and the TLR-2 induced
ROS production were two distinct pathways, which can be inde-
pendently targeted by TLR-2 activating agents.
Taken together, the present studies provide several important
insights. First, we showed that even mild CKD inverts HDL’s
endothelial-protective properties. In fact, HDLCKD inducesS and Inhibition of NO via a TLR-1- or TLR-6-Independent Pathway
alizing antibody or an isotype control antibody (10 mg/ml, 1 hr) and subsequent
althy and HDLCKD (15 mg/kg).
LR-6 neutralizing antibody or an isotype control (10 mg/ml, 1 hr) and stimulation
m3CSK4 treated cells, ## p < 0.01 compared FSL-1 treated cells).
ndependent experiments. See also Figure S4.
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Figure 6. Activation of Endothelial TLR-2 Inhibits eNOS Activating Pathways and Stimulates NADPH Oxidase via Phosphorylation of JNK
(A) Phosphorylation of Akt at Ser473, eNOS activating phosphorylation at Ser1177 and eNOS inhibiting phosphorylation at Thr495 determined by immunoblot
analysis in HAEC incubated with Pam3CSK4 (1 mg/ml) for 10 min.
(B) Endothelial superoxide production after preincubation with L-NAME (0.3 mM, 1 hr), a specific eNOS inhibitor, or VAS-2870 (10 mM, 1 hr), a specific NAPDH-
oxidase inhibitor and subsequent stimulation with Pam3CSK4 (1 mg/ml; 1 hr).
(C) Endothelial nitric oxide production after stimulation with Pam3CSK4 (1 mg/ml) or HDL (50 mg/ml) with or without preincubation with VAS-2870 (10 mM, 1 hr).
(D) Time-dependent effect of TLR-2 activation with Pam3CSK4 (1 mg/ml) on endothelial SAPK-JNK phosphorylation (***p < 0.001 compared to basal).
(E) Endothelial superoxide production after incubation with Pam3CSK4 (1 mg/ml) or HDL (50 mg/ml) for 1 hr with or without preincubation with SP600125, a SAPK-
JNK inhibitor (1 mM).
(F) Endothelial nitric oxide production after stimulation with Pam3CSK4 (1 mg/ml) or HDL (50 mg/ml) with or without preincubation with SP600125 (1 mM, 1 hr).
All data are presented as mean ± SEM and are representative for at least three independent experiments. See also Figure S5.
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Figure 7. Modified HDL Induces Endothelial Inflammation and Suppresses Endothelial Repair
(A) Reendothelialized area at day 3 after carotid injury and injection of HDLHealthy, HDLCKD, or HDLSDMA (15 mg/kg) in nude mice. PBS treated animals serve as
control.
(B) Representative photographs of carotid arteries after Evans Blue staining.
(C) Reendothelialized area at day 3 after carotid injury in Tlr2/mice with injection of HDLHealthy, HDLCKD, or HDLSDMA (15 mg/kg). PBS treated animals serve as
control.
(D) Adhesion of mononuclear cells (MNC) to TNF-a (5 ng/ml) treated endothelial cells after incubation with HDLHealthy or HDLCKD (50 mg/ml). MNC are stained with
DiI and HAEC with DAPI.
(legend continued on next page)
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Immunity
HDL Promotes Endothelial Dysfunction via TLR-2endothelial dysfunction, impairs endothelial repair, and
increases ABP. Second, we identified SDMA in HDLCKD as the
culprit that modifies HDL to induce these deleterious endothelial
effects. Moreover, we demonstrated that such modified HDL
activates endothelial TLR-2 signaling resulting in enhanced
ROS production and inhibition of endothelial NO bioavailability.
Third, our data provide evidence that these effects were medi-
ated by activation of TLR-2 via a TLR-1- or TLR-6-coreceptor-
independent alternative pathway. These data illustrate as to
how a small compound like SDMA can modify the HDL particle
mimicking a damage-associated molecular pattern to activate
TLR-2, thereby linking innate immunity, endothelial dysfunction,
and arterial hypertension.
Pharmacological therapies to raise HDL cholesterol serum
concentrations are currently in the focus of cardiovascular
research. Although epidemiological studies indicated that higher
HDL cholesterol serum concentrations are associated with
a reduced risk for cardiovascular events (Miller et al., 1977),
recent interventional trials using different approaches to raise
HDL cholesterol serum concentrations failed to demonstrate
a beneficial effect on CV mortality (Barter et al., 2007; Boden
et al., 2011; Schwartz et al., 2012). The present study could
provide an explanation for these findings to gain amore complex
picture of lipoprotein biology. Our results indicate that the
vascular effects of HDLHealthy and HDLCKD are completely
different. Therefore, it might be necessary to distinguish between
quantitative measurements of HDL serum concentrations and
qualitative examinations of HDL’s functionality. The present
study suggests that simply raising HDL in serum does imply
the restoration of HDL’s atheroprotective properties. Moreover,
HDL serum concentrations per se do not provide adjuvant infor-
mation on the biological function of HDL. Future research should
reveal strategies to evade detrimental remodeling of HDL under
disease conditions such as CKD.
EXPERIMENTAL PROCEDURES
Animals
WT (C57BL/6J), Tlr2–/– (B6.129-Tlr2tm1Kir/J), Tlr4/ (B6.B10ScN-Tlr4lps-del/
JthJ), and eNOS–/– (B6.129P2-Nos3tm1Unc/J) mice were obtained from The
Jackson Laboratory, Tlr1/ and Tlr6/ mice from OrientalBioService, and
CD1 (nu/nu) fromCharles River. Mice were housed andmaintained in the Saar-
land University Hospital Animal Facility. All animal studies were approved by
the animal ethics committee of the Saarland University and the University of
Zurich, respectively.
ESR Spectroscopy Analysis of NO Production in HAEC and BAEC
NO production was measured by ESR spectroscopy analysis with the use of
the spin-trap colloid Fe(DETC)2 as described previously (Kleschyov et al.,
2000; Sorrentino et al., 2010). Cells were stimulated with the isolated lipopro-
teins or Pam3CSK4, respectively, for 1 hr.
ESR Spectroscopy Analysis of Superoxide Production in HAEC
Endothelial superoxide was measured using ESR spectroscopy and the spin
trap 1-hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethylpyrrolidine (CMH) as
described previously (Landmesser et al., 2002; Sorrentino et al., 2010). Cells(E) Representative micrographs of high-power fields of six independent experim
(F) Effect ofHDLHealthy,HDLCKD, orHDLSDMA (50 mg/ml) with or without coincubatio
with DetaNO (1 mM) on TNF-a-induced (5 ng/ml) endothelial VCAM-1 expression
All data are presented as mean ± SEM and are representative for at least three i
766 Immunity 38, 754–768, April 18, 2013 ª2013 Elsevier Inc.were stimulated with the isolated lipoproteins or Pam3CSK4, respectively,
for 1 hr.
Blood Pressure Measurements in Mice
Systolic blood pressures were measured by a computerized tail-cuff system
(Visitech Systems) as described previously (Landmesser et al., 2002). On
each day of blood pressure determination, 20 measurements were obtained
and averaged for each mouse.
Bone-Marrow Transplantation
Bone-marrow transplantation experiments were performed as described
previously (Kania et al., 2009). In brief, 6- to 8-week-old WT or Tlr2/ mice
were lethally irradiated with 2 3 6.5 Gy by using Gammatron (Co-60) system
and reconstituted with 2 3 107 donor bone-marrow cells from WT or Tlr2/
mice, respectively. After reconstitution, all mice received prophylactic antibi-
otics in the drinking water and were housed in a specific pathogen-free envi-
ronment for 6 weeks.
Determination of Methylarginines by Using HPLC-ESI-MS/MS
Quantification of methylarginines (ADMA, SDMA) in serum samples as well as
in HDL fractions was performed as described previously with some modifica-
tions (Di Gangi et al., 2010).
Statistics
All data are expressed as mean ± SEM. Statistical comparisons were made by
one-way ANOVA or the nonparametric Kruskal-Wallis test. P value < 0.05 was
considered statistically significant. Post hoc Tukey test or Bonferroni adjust-
ment was performed for multiple comparisons. All analyses were performed
with GraphPad Prism (Version 4.0, GraphPad Software).
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